Eli Lilly’s Weight-Loss Boom Is Rewriting Big Pharma

Eli Lilly’s Weight-Loss Boom Is Rewriting Big Pharma

0 Anmeldelser
0
Afsnit
1458 of 1457
Længde
13M
Sprog
Engelsk
Format
Kategori
Fakta

Eli Lilly raised its full-year outlook after strong demand for its diabetes and obesity treatments drove a major jump in revenue and profit.

In this episode, we look at how GLP-1 drugs have become one of the most important growth engines in health care—and why the competition to own this market is only getting fiercer.

The bigger story is what happens when one product category grows so fast that it reshapes an entire company’s strategy, valuation, and future.

Support the Show

• Amazon picks: https://amzn.to/4fUGHEm

• Amazon picks: https://amzn.to/4pUHt8Q

• Amazon picks: https://amzn.to/45a4MC9

• Need a website or app? https://hireawebteam.com

• Support us on Patreon: https://www.patreon.com/c/StageZeroNews?view_as=patron&vanity=StageZeroNews

• Subscribe on Supercast: https://clubelon.supercast.com/

Disclosure: Amazon links may earn a commission from qualifying purchases.


Lyt når som helst, hvor som helst

Nyd den ubegrænsede adgang til tusindvis af spændende e- og lydbøger - helt gratis

  • Lyt og læs så meget du har lyst til
  • Opdag et kæmpe bibliotek fyldt med fortællinger
  • Eksklusive titler + Mofibo Originals
  • Opsig når som helst
Prøv nu
Cover for Eli Lilly’s Weight-Loss Boom Is Rewriting Big Pharma

Other podcasts you might like ...